MedTrace Logo

Clinical Performance Evaluation of DxN HBV Assay

NCT03123159 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-07-12

No results posted yet for this study

Summary

The DxN Hepatitis B Virus (HBV) Assay is an in vitro diagnostic assay intended as an aid in the management of HBV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HBV Assay for plasma samples in the intended use population.

Conditions

Interventions

DIAGNOSTIC_TEST

DxN HBV Assay

Molecular diagnostic test to detect Hepatitis B

Sponsors & Collaborators

  • Beckman Coulter, Inc.

    lead INDUSTRY

Principal Investigators

  • Lori Lofaro, MSHS · Beckman Coulter

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-27
Primary Completion
2017-08-30
Completion
2017-08-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03123159 on ClinicalTrials.gov